Literature DB >> 28684456

Optimization of DSC MRI Echo Times for CBV Measurements Using Error Analysis in a Pilot Study of High-Grade Gliomas.

L C Bell1, M D Does2, A M Stokes1, L C Baxter1, K M Schmainda3, A C Dueck4, C C Quarles5.   

Abstract

BACKGROUND AND
PURPOSE: The optimal TE must be calculated to minimize the variance in CBV measurements made with DSC MR imaging. Simulations can be used to determine the influence of the TE on CBV, but they may not adequately recapitulate the in vivo heterogeneity of precontrast T2*, contrast agent kinetics, and the biophysical basis of contrast agent-induced T2* changes. The purpose of this study was to combine quantitative multiecho DSC MRI T2* time curves with error analysis in order to compute the optimal TE for a traditional single-echo acquisition.
MATERIALS AND METHODS: Eleven subjects with high-grade gliomas were scanned at 3T with a dual-echo DSC MR imaging sequence to quantify contrast agent-induced T2* changes in this retrospective study. Optimized TEs were calculated with propagation of error analysis for high-grade glial tumors, normal-appearing white matter, and arterial input function estimation.
RESULTS: The optimal TE is a weighted average of the T2* values that occur as a contrast agent bolus transverses a voxel. The mean optimal TEs were 30.0 ± 7.4 ms for high-grade glial tumors, 36.3 ± 4.6 ms for normal-appearing white matter, and 11.8 ± 1.4 ms for arterial input function estimation (repeated-measures ANOVA, P < .001).
CONCLUSIONS: Greater heterogeneity was observed in the optimal TE values for high-grade gliomas, and mean values of all 3 ROIs were statistically significant. The optimal TE for the arterial input function estimation is much shorter; this finding implies that quantitative DSC MR imaging acquisitions would benefit from multiecho acquisitions. In the case of a single-echo acquisition, the optimal TE prescribed should be 30-35 ms (without a preload) and 20-30 ms (with a standard full-dose preload).
© 2017 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28684456      PMCID: PMC5591773          DOI: 10.3174/ajnr.A5295

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  21 in total

1.  Comparative studies on the efficacy of MRI contrast agents in MRA.

Authors:  Hanns-Joachim Weinmann; Hans Bauer; Wolfgang Ebert; Thomas Frenzel; Bernd Radüchel; Johannes Platzek; Heribert Schmitt-Willich
Journal:  Acad Radiol       Date:  2002-05       Impact factor: 3.173

2.  Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)-MRI estimates of cerebral blood volume (CBV) in human gliomas.

Authors:  Benjamin M Ellingson; Taryar Zaw; Timothy F Cloughesy; Kourosh M Naeini; Shadi Lalezari; Sandy Mong; Albert Lai; Phioanh L Nghiemphu; Whitney B Pope
Journal:  J Magn Reson Imaging       Date:  2012-01-26       Impact factor: 4.813

3.  Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements.

Authors:  L S Hu; L C Baxter; K A Smith; B G Feuerstein; J P Karis; J M Eschbacher; S W Coons; P Nakaji; R F Yeh; J Debbins; J E Heiserman
Journal:  AJNR Am J Neuroradiol       Date:  2008-12-04       Impact factor: 3.825

4.  Bayesian analysis of neuroimaging data in FSL.

Authors:  Mark W Woolrich; Saad Jbabdi; Brian Patenaude; Michael Chappell; Salima Makni; Timothy Behrens; Christian Beckmann; Mark Jenkinson; Stephen M Smith
Journal:  Neuroimage       Date:  2008-11-13       Impact factor: 6.556

5.  Signal-to-noise analysis of cerebral blood volume maps from dynamic NMR imaging studies.

Authors:  J L Boxerman; B R Rosen; R M Weisskoff
Journal:  J Magn Reson Imaging       Date:  1997 May-Jun       Impact factor: 4.813

6.  Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion-weighted magnetic resonance imaging.

Authors:  Antonio C M Maia; Suzana M F Malheiros; Antonio J da Rocha; João N Stávale; Iara F Guimarães; Lia R R Borges; Adrialdo J Santos; Carlos J da Silva; Julieta G S P de Melo; Oreste P Lanzoni; Alberto A Gabbai; Fernando A P Ferraz
Journal:  J Neurosurg       Date:  2004-12       Impact factor: 5.115

7.  A simplified spin and gradient echo approach for brain tumor perfusion imaging.

Authors:  Ashley M Stokes; C Chad Quarles
Journal:  Magn Reson Med       Date:  2015-03-05       Impact factor: 4.668

8.  Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla.

Authors:  Jörg Pintaske; Petros Martirosian; Hansjörg Graf; Gunter Erb; Klaus-Peter Lodemann; Claus D Claussen; Fritz Schick
Journal:  Invest Radiol       Date:  2006-03       Impact factor: 6.016

9.  Effects of echo time variation on perfusion assessment using dynamic susceptibility contrast MR imaging at 3 tesla.

Authors:  O Thilmann; E-M Larsson; I M Björkman-Burtscher; F Ståhlberg; R Wirestam
Journal:  Magn Reson Imaging       Date:  2004-09       Impact factor: 2.546

10.  Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation?

Authors:  Nasuda Danchaivijitr; Adam D Waldman; Daniel J Tozer; Christopher E Benton; Gisele Brasil Caseiras; Paul S Tofts; Jeremy H Rees; H Rolf Jäger
Journal:  Radiology       Date:  2008-04       Impact factor: 11.105

View more
  2 in total

1.  Systematic assessment of multi-echo dynamic susceptibility contrast MRI using a digital reference object.

Authors:  Ashley M Stokes; Natenael B Semmineh; Ashley Nespodzany; Laura C Bell; C Chad Quarles
Journal:  Magn Reson Med       Date:  2019-08-09       Impact factor: 4.668

2.  Evaluation of single bolus, dual-echo dynamic susceptibility contrast MRI protocols in brain tumor patients.

Authors:  Ashley M Stokes; Maurizio Bergamino; Lea Alhilali; Leland S Hu; John P Karis; Leslie C Baxter; Laura C Bell; C Chad Quarles
Journal:  J Cereb Blood Flow Metab       Date:  2021-08-20       Impact factor: 6.960

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.